📣 VC round data is live. Check it out!

Jeol Valuation Multiples

Discover revenue and EBITDA valuation multiples for Jeol and similar public comparables like NovoCure, Santec Holdings, Beijing Balance Medical, Establishment Labs and more.

Jeol Overview

About Jeol

Jeol Ltd is engaged in the manufacture and sale of scientific and measuring instruments, industrial equipment, and medical equipment. The group has three reportable segments: Scientific and Measuring Instruments, Industrial Equipment, and Medical Equipment. The Scientific and Measuring Instruments segment manufactures and sells electron microscopes, nuclear magnetic resonance devices, and mass spectrometers. The Industrial Equipment segment manufactures and sells electron beam lithography equipment, electron beam metal 3D printers, and high-frequency power supplies. The Medical Equipment segment manufactures and sells automatic analyzers and related products. It generates the majority of its revenue from the Scientific and Measuring Instruments segment.


Founded

1949

HQ

Japan

Employees

3.6K

Website

jeol.co.jp

Financials (LTM)

Revenue: $1B
EBITDA: $199M

EV

$2B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Jeol Financials

Jeol reported last 12-month revenue of $1B and EBITDA of $199M.

In the same LTM period, Jeol generated $199M in EBITDA and $126M in net income.

Revenue (LTM)


Jeol P&L

In the most recent fiscal year, Jeol reported revenue of $1B and EBITDA of $278M.

Jeol is profitable as of last fiscal year, with gross margin of 44%, EBITDA margin of 21%, and net margin of 10%.

See analyst estimates for Jeol
LTMLast FY202320242025202620272028
Revenue$1B$1B$1B$1B$1B
Gross Profit$589M$495M$568M$589M
Gross Margin44%45%47%50%
EBITDA$199M$278M$210M$199M$195M
EBITDA Margin17%21%19%16%16%
EBIT Margin14%18%16%18%15%
Net Profit$126M$128M$132M$124M$123M
Net Margin11%10%12%10%10%

Financial data powered by Morningstar, Inc.

Jeol Stock Performance

Jeol has current market cap of $2B, and enterprise value of $2B.

Market Cap Evolution


Jeol's stock price is $42.03.

Jeol share price increased by 7.3% in the last 30 days, and by 65.0% in the last year.

Jeol has an EPS (earnings per share) of $2.63.

See more trading valuation data for Jeol
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$2B$2B1.1%7.3%-3.1%65.0%$2.63

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Jeol Valuation Multiples

Jeol trades at 1.6x EV/Revenue multiple, and 9.4x EV/EBITDA.

See NTM and 2027E valuation multiples for Jeol

EV / Revenue (LTM)


Jeol Financial Valuation Multiples

As of May 9, 2026, Jeol has market cap of $2B and EV of $2B.

Jeol has a P/E ratio of 16.2x.

LTMLast FY202320242025202620272028
EV/Revenue1.6x1.4x1.7x1.5x1.6x
EV/EBITDA9.4x6.8x9.0x9.4x9.6x
EV/EBIT11.3x7.7x11.1x8.8x10.5x
EV/Gross Profit3.2x3.8x3.3x3.2x
P/E16.2x16.0x15.5x16.5x16.6x
EV/FCF15.7x36.4x17.3x15.7x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Jeol Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Jeol Margins & Growth Rates

Jeol decreased revenue by 14% and EBITDA by 29% in the last fiscal year.

In the most recent fiscal year, Jeol reported gross margin of 44%, EBITDA margin of 21%, and net margin of 10%.

See estimated margins and future growth rates for Jeol

Jeol Margins

Last FY202420252026202720282029
Gross Margin44%47%50%
EBITDA Margin21%16%16%19%
EBIT Margin18%18%15%16%
Net Margin10%10%10%12%
FCF Margin9%9%10%

Jeol Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(14%)11%(3%)(3%)
Gross Profit Growth15%4%
EBITDA Growth(29%)(5%)(2%)11%
EBIT Growth(33%)26%(16%)2%
Net Profit Growth(3%)(6%)(1%)10%
FCF Growth111%10%

Data powered by FactSet, Inc. and Morningstar, Inc.

Jeol Operational KPIs

Jeol's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.

Jeol's Rule of 40 is 15% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Jeol's Rule of X is 10% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Jeol
LTMLast FY202320242025202620272028
Rule of 4016%15%
Bessemer Rule of X14%10%
Revenue per Employee$0.4M
Opex per Employee$0.1M
R&D Expenses to Revenue6%6%6%6%
Opex to Revenue27%30%29%31%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
NovoCure2.9x2.8x(54.6x)(77.6x)
Santec Holdings12.4x10.4x37.0x
Beijing Balance Medical21.7x54.0x
Establishment Labs10.9x9.9x(161.6x)(760.2x)
MicroPort Scientific2.6x2.6x18.0x15.2x
Tecan Group1.8x1.8x11.8x11.7x
Bausch Health2.1x2.1x6.8x5.9x
Vaisala3.1x3.0x16.2x15.7x

This data is available for Pro users. Sign up to see all Jeol competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Jeol

When was Jeol founded?Jeol was founded in 1949.
Where is Jeol headquartered?Jeol is headquartered in Japan.
How many employees does Jeol have?As of today, Jeol has over 3K employees.
Who is the CEO of Jeol?Jeol's CEO is Izumi Oi.
Is Jeol publicly listed?Yes, Jeol is a public company listed on Tokyo Stock Exchange.
What is the stock symbol of Jeol?Jeol trades under 6951 ticker.
When did Jeol go public?Jeol went public in 1962.
Who are competitors of Jeol?Jeol main competitors include NovoCure, Santec Holdings, Beijing Balance Medical, Establishment Labs, MicroPort Scientific, Tecan Group, Bausch Health, Vaisala, AddLife, Qingdao Baheal Medical.
What is the current market cap of Jeol?Jeol's current market cap is $2B.
What is the current revenue of Jeol?Jeol's last 12 months revenue is $1B.
What is the current revenue growth of Jeol?Jeol revenue growth (NTM/LTM) is (1%).
What is the current EV/Revenue multiple of Jeol?Current revenue multiple of Jeol is 1.6x.
Is Jeol profitable?Yes, Jeol is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Jeol?Jeol's last 12 months EBITDA is $199M.
What is Jeol's EBITDA margin?Jeol's last 12 months EBITDA margin is 17%.
What is the current EV/EBITDA multiple of Jeol?Current EBITDA multiple of Jeol is 9.4x.
How many companies Jeol has acquired to date?Jeol hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Jeol has invested to date?Jeol hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Jeol

Lists including Jeol

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial